CDK

Cat. No.

A54243

CAS No.

1453833-30-1

LDC3140

LDC3140 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of less than 5 nM. By targeting CDK7, LDC3140 disrupts cell cycle regulation, resulting in cell cycle arrest and reduced proliferation of tumor cells. This compound serves as a valuable tool for research focused on cancer therapeutics and the mechanistic understanding of cell cycle dynamics in cancer biology.

Cat. No.

A54244

CAS No.

3542-63-0

CDK9-IN-10

CDK9-IN-10 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), effectively targeting the transcriptional regulation pathways. This compound serves as a crucial ligand for the PROTAC CDK9 degrader-2, facilitating targeted degradation of CDK9 in cellular studies. Its applications include investigations into oncogenic processes and transcriptional dysregulation, making it a valuable tool for cancer research and drug discovery.

Cat. No.

A54245

CAS No.

2650640-17-6

CDK9-IN-14

CDK9-IN-14 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 value of 6.92 nM. This compound demonstrates significant inhibitory activity against MV4;11 cells and exhibits efficacy in in vivo tumor models. Additionally, CDK9-IN-14 shows favorable selectivity and a low toxicity profile, making it suitable for various cancer research applications aimed at targeting transcriptional regulation pathways.

Cat. No.

A54247

CAS No.

2250279-81-1

Atuveciclib S-Enantiomer

Synonyms: BAY-1143572 S-Enantiomer

Atuveciclib S-Enantiomer is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9). With an IC50 of 16 nM, it effectively inhibits the CDK9/CycT1 complex, playing a crucial role in regulating transcription and cell cycle progression. This compound is primarily utilized in research applications targeting cancer therapeutics and studying transcriptional regulation mechanisms.

Cat. No.

A54248

CAS No.

1957203-02-9

CDK7-IN-1

CDK7-IN-1 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound effectively modulates CDK7 activity, disrupting cell cycle progression and transcription regulation. CDK7-IN-1 is suitable for research applications related to cancer biology and therapeutic development targeting aberrant cell proliferation.

Cat. No.

A54249

CAS No.

2733342-93-1

(S)-LY3177833 hydrate

(S)-LY3177833 hydrate is a selective inhibitor of CDC7 kinase, playing a crucial role in DNA replication and cell cycle regulation. This compound exhibits significant in vitro anticancer activity across various cancer cell lines, making it a valuable tool for studying cancer biology. Its application in research extends to investigations of cell proliferation and therapeutic strategies targeting DNA replication mechanisms.

Cat. No.

A54250

CAS No.

2055741-39-2

IV-361

IV-361 is a selective cyclin-dependent kinase 7 (CDK7) inhibitor with a Ki value of less than 50 nM. This compound exhibits significant anti-cancer activity, making it a valuable tool for researchers investigating cancer cell proliferation and survival pathways. IV-361's specificity for CDK7 allows for in-depth studies of its role in transcription regulation and potential therapeutic applications in cancer treatment.

Cat. No.

A54251

CAS No.

1627696-53-0

LY3177833 monhydrate

LY3177833 monhydrate is a potent CDC7 inhibitor, demonstrating an IC50 of 3.3 nM, alongside its activity against pMCM2 with an IC50 of 290 nM. This compound is recognized for its ability to induce cellular senescence, making it a valuable tool in cancer research and studies related to cell cycle regulation. Its oral bioavailability enhances its applicability in in vivo studies, facilitating the exploration of CDC7-targeted therapeutic strategies.

Cat. No.

A54252

CAS No.

1402057-86-6

Cdc7-IN-5

Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase, a crucial serine-threonine protein kinase that plays a key role in the initiation of DNA replication during the cell cycle. This compound serves as a valuable tool for investigating the regulation of DNA replication and cell cycle progression. Its application extends to studying cancer biology and potential therapeutic interventions targeting DNA replication mechanisms.

Cat. No.

A54253

CAS No.

2408872-84-2

Cimpuciclib tosylate

Cimpuciclib tosylate is a potent selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 0.49 nM. Its strong inhibitory activity is associated with anti-tumor effects and promotes cell cycle arrest in cancer research. This compound is valuable for studies focused on tumor proliferation and therapeutic strategies targeting CDK4 in various cancer types.

Cat. No.

A54254

CAS No.

546102-60-7

CDK4/6-IN-18

CDK4/6-IN-18 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates the ability to effectively inhibit ionizing radiation-induced DNA damage in cellular models. This compound is a valuable tool for research focused on cancer biology and therapies that target the cell cycle and DNA damage response pathways.

Cat. No.

A54255

CAS No.

2743517-28-2

CDK6-IN-1

CDK6-IN-1 is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), functioning primarily by impeding cell growth and promoting G1-phase cell cycle arrest. This compound has significant implications in cancer research, particularly in studies targeting cell proliferation and tumorigenesis. Its efficacy in modulating cell cycle progression makes it a valuable tool for investigating mechanisms of cancer therapy and the role of CDK6 in malignancies.

Cat. No.

A54256

CAS No.

2796279-20-2

JNJ-3738

JNJ-3738 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with a Ki value of 21.75 nM. This compound demonstrates potent inhibitory activity in CDK7 wild-type expressing A549 cells, exhibiting a pIC50 of 7.37. JNJ-3738 is primarily utilized in research applications focused on cell cycle regulation, transcriptional control, and cancer biology.

Cat. No.

A54257

CAS No.

3083777-51-6

(S)-CDK2 degrader 6

(S)-CDK2 degrader 6 selectively targets cyclin-dependent kinase 2 (CDK2) as a molecular glue degrader. With a DC50 of 166.7 nM over 24 hours, this compound effectively promotes the degradation of CDK2, thereby modulating cell cycle progression. It holds significant potential for applications in breast cancer research, enabling the exploration of therapeutic strategies that involve the regulation of CDK2 activity.

Cat. No.

A54258

CAS No.

2883700-83-0

PPA-037

PPA-037 is a potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12) with oral bioavailability. By inducing the degradation of cyclin K, PPA-037 enhances antiproliferative effects on various tumor cells. This compound holds significant potential for cancer research applications focused on targeting CDK12-related pathways.

Cat. No.

A54259

CAS No.

189064-08-2

[Ala92]-p16 (84-103)

[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a tumor suppressor protein that targets CDK4-Cyclin D1 kinase. This peptide effectively binds to CDK4 and CDK6, demonstrating an inhibitory effect on CDK4-cyclin D1 activity with an IC50 of 1.5 μM. Its mechanism of action leads to the blockade of cell cycle progression through the G1 phase, making it a valuable reagent for cancer research and studies focusing on cell cycle regulation.

Cat. No.

A54260

CAS No.

3068546-95-9

DS17

DS17 is a molecular glue that functions as a potent degrader of cyclin K, exhibiting an EC50 value of 13 nM. This compound is pivotal for cancer research due to its ability to modulate cell cycle dynamics and influence tumor progression. Researchers can utilize DS17 to investigate the therapeutic potential of targeting cyclin K in various malignancies.

Cat. No.

A54262

CAS No.

685097-43-2

SNX7

SNX7 is a selective inhibitor of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. This compound plays a crucial role in studying cellular senescence and various CDKI-related diseases. By targeting the CDKI pathway, SNX7 serves as a valuable tool in cancer research and other conditions where cell cycle regulation is disrupted.

Cat. No.

A54263

CAS No.

3029608-57-6

CDK12/13-IN-3

CDK12/13-IN-3 is a selective inhibitor of cyclin-dependent kinases 12 and 13, demonstrating IC50 values of 107.4 nM and 79.4 nM, respectively. This compound effectively inhibits the phosphorylation of Ser2 on the C-terminal domain of RNA polymerase II, leading to DNA damage and downregulation of DNA damage response gene expression. CDK12/13-IN-3 exhibits notable antiproliferative activity against a variety of cancer cell lines and shows significant antitumor effects in mouse models, supported by favorable pharmacokinetic properties, including an oral bioavailability of 53.6%.

Cat. No.

A54265

CAS No.

2700286-66-2

XPW1

XPW1 is a potent and selective inhibitor of CDK9, a key regulator in transcriptional control linked to cancer progression. This compound exhibits significant anti-tumor activity against clear cell renal cell carcinoma (ccRCC) and demonstrates favorable toxicity profiles. Its unique mechanism of action makes it a valuable tool for research into CDK9's role in cancer biology and therapeutic interventions.

Cat. No.

A54266

CAS No.

3034082-58-8

CDK7-IN-28

CDK7-IN-28 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 5 nM. This compound effectively impedes cell proliferation in the MDA-MB-468 cell line by interfering with cell cycle progression and inhibiting DNA replication. Its activity makes it a valuable tool for research into cell cycle regulation and cancer therapeutics.

Cat. No.

A54267

CAS No.

3054692-62-2

CDK2-IN-37

CDK2-IN-37 is a selective cyclin-dependent kinase 2 (CDK2) inhibitor that demonstrates significant anti-cancer properties. By effectively inhibiting CDK2 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. This compound is a valuable tool for researchers investigating the role of CDK2 in cancer biology and therapeutic development.

Cat. No.

A54268

CAS No.

2095433-94-4

(E/Z)-THZ1 dihydrochloride

(E/Z)-THZ1 dihydrochloride is a potent and selective inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 3.2 nM. This compound exhibits significant antiproliferative activity, making it a valuable tool for research in cancer biology and cell cycle regulation. Its ability to inhibit CDK7 can be utilized in studies aimed at understanding transcriptional regulation and therapeutic strategies for various malignancies.

Cat. No.

A54269

CAS No.

91147-18-1

(S)-(-)-O-Demethylbuchenavianine

(S)-(-)-O-Demethylbuchenavianine is a flavonoidal alkaloid that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1 and CDK5 with IC50 values of 0.03 and 0.05 μM, respectively. This compound is valuable for research applications focused on cell cycle regulation and the investigation of CDK-related signaling pathways. Its inhibitory activity makes it an important tool for studying the role of CDKs in various biological processes and diseases.

Cat. No.

A54270

CAS No.

1256963-02-6

CDK4-IN-1

CDK4-IN-1 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 10 nM. This compound demonstrates significant specificity, being 1500-fold and 500-fold less potent against CDK1/Cyclin B and CDK2/Cyclin A, respectively, with IC50 values greater than 15 µM and 5 µM. CDK4-IN-1 is primarily utilized in research focused on cell cycle regulation and anti-cancer therapies, particularly in the context of cancers characterized by aberrant CDK4 activity.